AEB071 is primarily investigated for its immunomodulatory properties, particularly in the context of autoimmune diseases and organ transplantation. It functions by selectively inhibiting protein kinase C (PKC) isoforms, especially PKCθ, which plays a key role in T-cell activation. By suppressing T-cell signaling, AEB071 helps reduce immune responses that contribute to tissue damage in autoimmune conditions such as type 1 diabetes and psoriasis. In preclinical and clinical studies, AEB071 has shown potential in preventing T-cell-mediated destruction of insulin-producing beta cells, making it a candidate for preserving residual insulin secretion in newly diagnosed type 1 diabetes patients. It has also been explored for use in transplant medicine to prevent graft rejection without the broad immunosuppressive effects associated with traditional therapies. Additionally, due to its targeted mechanism, AEB071 offers a favorable safety profile compared to global immunosuppressants, reducing the risk of infections and malignancies. Research continues to evaluate its long-term efficacy and optimal therapeutic applications in immune-related disorders.